Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.

The application of Cre/loxP technology has resulted in a new generation of conditional mouse models of prostate cancer. Here, we describe the improvement of the conditional Pten deletion model of prostate adenocarcinoma by combining it with either a conditional luciferase or enhanced green fluorescent protein reporter line. In these models, the recombination mechanism that inactivates the Pten alleles also activates the reporter gene. In the luciferase reporter model, the growth of the primary cancer can be followed noninvasively by bioluminescence imaging (BLI). Surgical castration of tumor-bearing animals leads to a reduced bioluminescence signal corresponding to tumor regression that is verified at necropsy. When castrated animals are maintained, the emergence of androgen depletion-independent cancer is detected using BLI at times varying from 7 to 28 weeks postcastration. The ability to monitor growth, regression, or relapse of the tumor with the use of BLI lead to the collection of tumors at different stages of development. By comparing the distribution of phenotypically distinct populations of epithelial cells in cancer tissues, we noted that the degree of hyperplasia of cells with neuroendocrine differentiation significantly increases in the recurrent cancer relative to the primary cancer, a characteristic which may parallel the appearance of a neuroendocrine phenotype in human androgen depletion-independent cancer. The enhanced green fluorescent protein model, at necropsy, can provide an opportunity to locate or assess tumor volume or to isolate enriched populations of cancer cells from tumor tissues via fluorescence-based technologies. These refined models should be useful in the elucidation of mechanisms of prostate cancer progression, and for the development of approaches to preclinical intervention.

[1]  A. DeMaria,et al.  Diagnostic, Prognostic and Therapeutic Implications , 1974 .

[2]  G Dhom,et al.  Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate , 1991, The Prostate.

[3]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. , 1992 .

[4]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in human prostatic carcinoma , 1992 .

[5]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in human prostatic carcinoma. , 1992, Human pathology.

[6]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications , 1992, Cancer.

[7]  P. di Sant'Agnese,et al.  Neuroendocrine cells in the human prostate gland. , 1993, Journal of andrology.

[8]  C. Logothetis,et al.  Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. , 1993, The Journal of urology.

[9]  K Remberger,et al.  Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. , 1995, Human pathology.

[10]  A. Partin,et al.  Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.

[11]  N. Rubio,et al.  Metastatic burden in nude mice organs measured using prostate tumor PC‐3 cells expressing the luciferase gene as a quantifiable tumor cell marker , 2000, The Prostate.

[12]  T. H. van der Kwast,et al.  Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. , 2000, Cancer research.

[13]  R. Matusik,et al.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. , 2000, Endocrinology.

[14]  T. Kwast,et al.  Androgen Deprivation of the Prohormone Convertase-310 Human Prostate Cancer Model System Induces Neuroendocrine Differentiation , 2000 .

[15]  R. Young,et al.  Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis , 2000 .

[16]  N. Greenberg,et al.  Prostate specific expression of Cre recombinase in transgenic mice , 2000, Genesis.

[17]  Jos Jonkers,et al.  A highly efficient ligand‐regulated Cre recombinase mouse line shows that LoxP recombination is position dependent , 2001, EMBO reports.

[18]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Tachibana,et al.  Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. , 2001, Oncology reports.

[20]  M. Poutanen,et al.  Improved technique for detection of enhanced green fluorescent protein in transgenic mice. , 2001, BioTechniques.

[21]  P. Roy-Burman,et al.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.

[22]  B. Rice,et al.  In vivo imaging of light-emitting probes. , 2001, Journal of biomedical optics.

[23]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Y Fujiwara,et al.  Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. , 2001, Blood.

[25]  P. Roy-Burman,et al.  Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. , 2002, Cancer research.

[26]  N. Rubio,et al.  Combined Noninvasive Imaging and Luminometric Quantification of Luciferase-Labeled Human Prostate Tumors and Metastases , 2002, Laboratory Investigation.

[27]  S. Gambhir,et al.  Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging , 2002, Nature Medicine.

[28]  Peter A. Humphrey,et al.  Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia , 2002, Molecular and Cellular Biology.

[29]  M. Groszer,et al.  Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene , 2002, Genesis.

[30]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[31]  Anton Berns,et al.  The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. , 2003, Cancer research.

[32]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[33]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[34]  P. Abrahamsson Neuroendocrine differentiation in prostatic carcinoma , 1999, The Prostate.

[35]  D. Jenkins,et al.  Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis , 2004, Clinical & Experimental Metastasis.

[36]  C. Scatena,et al.  Imaging of bioluminescent LNCaP‐luc‐M6 Tumors: A new animal model for the study of metastatic human prostate cancer , 2004, The Prostate.

[37]  Xiaoming Xie,et al.  The EZC-prostate model: noninvasive prostate imaging in living mice. , 2004, Molecular endocrinology.

[38]  P. Abrahamsson,et al.  Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. , 2005, European urology.

[39]  T. H. van der Kwast,et al.  Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. , 2005, Cancer research.

[40]  S. Lyons Advances in imaging mouse tumour models in vivo , 2005, The Journal of pathology.

[41]  D. Tindall,et al.  Letter to the Editor: Androgens and Prostate Cancer: Are the Descriptors Valid? , 2005, Cancer biology & therapy.

[42]  W. D. Martin,et al.  A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. , 2005, Journal of molecular endocrinology.

[43]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[44]  C. Sawyers,et al.  Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. , 2006, Cancer research.

[45]  S. Lyons,et al.  Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. , 2006, Cancer research.

[46]  P. di Sant'Agnese,et al.  Immunohistochemical characterization of neuroendocrine cells in prostate cancer , 2006, The Prostate.

[47]  Hong Wu,et al.  Increased expression of osteopontin contributes to the progression of prostate cancer. , 2006, Cancer research.

[48]  Shunyou Wang,et al.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Chun-Peng Liao,et al.  Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. , 2006, Cancer research.

[50]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.